Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Valsamo Anagnostou(Johns Hopkins University), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Elad Sharon(National Cancer Institute), Laura Q.M. Chow(The University of Texas at Austin), Mark Yarchoan(Sidney Kimmel Comprehensive Cancer Center), Deborah Collyar(Advocates for Youth), Franco Verde(Bloomberg (United States)), Hao Wang(Johns Hopkins University), Aaron R. Hansen(Princess Margaret Cancer Centre)
Cited by 181
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
|Cancer Discovery|2016|897